Evidence map›Paper›PMID 41211038›Full record

ArticleThe Pan African medical journal2025

Vaccines as antimicrobial resistance control tools: evidence from pneumococcal conjugate vaccines in South Africa.

Chinwe Iwu-Jaja, Akhona Victress Mazingisa, Anelisa Jaca, Chidozie Declan Iwu, Charles Shey Wiysonge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chinwe Iwu-JajaWorld Health Organization, Regional Office for Africa, Brazzaville, Congo.
Akhona Victress MazingisaDepartment of Community Health Studies, Faculty of Health Sciences, Durban University of Technology, Durban 4001, South Africa.
Anelisa JacaCochrane South Africa, South African Medical Research Council, Cape Town, South Africa.
Chidozie Declan IwuSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Charles Shey WiysongeWorld Health Organization, Regional Office for Africa, Brazzaville, Congo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The Expanded Programme on Immunisation demonstrated remarkable success for 50 years, accounting for 52% reduction in infant mortality in Africa. As antimicrobial resistance (AMR) continues to be a threat in Africa, responsible for 250,000 deaths in WHO African region in 2019, vaccines offer proven solutions. Studies from South Africa demonstrate that pneumococcal conjugate vaccines significantly reduced drug-resistant pneumococcal infections, with 67-96% reductions in resistant strains. Increasing immunisation coverage in Africa, reduces disease burden while providing a cost-effective strategy to combat antimicrobial resistance.

Indexed as

Pneumococcal InfectionsPneumococcal VaccinesAnti-Bacterial AgentsCost-Benefit AnalysisDrug Resistance, BacterialHumansImmunization ProgramsInfantSouth AfricaStreptococcus pneumoniaeVaccination CoverageVaccines, ConjugateAnti-Bacterial AgentsPneumococcal VaccinesVaccines, ConjugateAfricaAntimicrobial resistanceimmunisationimpact of vaccines on antimicrobial resistancepneumococcal conjugate vaccinesvaccine uptake

Identifiers

PMID41211038
PMCPMC12595554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.